Abivax Gets a $160 Boost: Jefferies Sees 'Differentiated' Obefazimod as UC Game-Changer
Jefferies starts Abivax coverage with Buy rating and $160 target. Views obefazimod as differentiated UC therapy; Q2 maintenance data de-risked for approval path.
/ 7 items
#ABVX↓
Abivax Rejects Rumors of Exclusive AstraZeneca Due Diligence Until March 23
French biotech company Abivax strongly rejects media claims that it gave AstraZeneca secret access to its data for a possible buyout until March 23, calling the reports "unfounded rumors."
AstraZeneca Leads Bid for Abivax as Eli Lilly Waits in the Wings
AstraZeneca gains exclusive data access to acquire surging French biotech Abivax (up 1,600% in 2025) before March 23 deadline; Eli Lilly waits in wings amid IBD drug promise.
AstraZeneca Rumored to Bid €176 Per Share for French Biotech Abivax Amid M&A Buzz
Abivax shares jump 6% on reports of AstraZeneca's €176-per-share offer for the French inflammatory disease drugmaker, adding to ongoing acquisition speculation.
Eli Lilly Eyes €15 Billion Abivax Acquisition Amid Drug Success
Abivax shares surge 4% on reports of Eli Lilly's €15B buyout interest. The French biotech's experimental ulcerative colitis drug obefazimod attracts big pharma attention after trial success.
Eli Lilly Eyes French Biotech Abivax for Ulcerative Colitis Drug Deal
Pharma giant Eli Lilly considers acquiring French biotech Abivax for its promising ulcerative colitis treatment, expected to launch in 2027.